Filters: Keyword is Opioid-Related Disorders [Clear All Filters]
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia." Drug and alcohol dependence 124, no. 1-2 (2012): 177-80. Abstract
"Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment." The International journal on drug policy 25, no. 1 (2014): 22-5. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction." AIDS (London, England) 19, no. 15 (2005): 1635-41. Abstract
"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance." Antimicrobial agents and chemotherapy 57, no. 12 (2013): 6154-7. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Initial strategies for integrating buprenorphine into HIV care settings in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S191-6. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"Illicit use of opioids: is OxyContin a "gateway drug"?" The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 16, no. 3 (2007): 166-73. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications." The International journal on drug policy 18, no. 4 (2007): 326-8. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S62-7. Abstract
"Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone." Alcoholism, clinical and experimental research 36, no. 2 (2012): 318-24. Abstract
"Guideline development for office-based pharmacotherapies for opioid dependence." Journal of addictive diseases 22, no. 4 (2003): 109-20. Abstract
"Group-based strategies for stress reduction in methadone maintenance treatment: what do patients want?" Journal of addiction medicine 5, no. 3 (2011): 181-7. Abstract
"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females." The pharmacogenomics journal 14, no. 3 (2014): 303-8. Abstract
"Gender and non-medical use of prescription opioids: results from a national US survey." Addiction (Abingdon, England) 103, no. 2 (2008): 258-68. Abstract
"Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 25, no. 4 (2004): 35-40. Abstract
"Factors affecting willingness to provide buprenorphine treatment." Journal of substance abuse treatment 36, no. 3 (2009): 244-51. Abstract
"Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients." The journal of pain : official journal of the American Pain Society 12, no. 1 (2011): 22-8. Abstract
"Evaluation of a combined online and in person training in the use of buprenorphine." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 27, no. 3 (2006): 39-45. Abstract
"Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007." Drug and alcohol dependence 115, no. 3 (2011): 221-8. Abstract
"Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program." The American journal of drug and alcohol abuse 39, no. 4 (2013): 247-51. Abstract
"Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone." Journal of general internal medicine 25, no. 7 (2010): 670-4. Abstract
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 4-16. Abstract
"Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 15, no. 1 (2006): 23-34. Abstract
"Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States." Addiction (Abingdon, England) 103, no. 6 (2008): 979-89. Abstract
"Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication." The American journal of drug and alcohol abuse 38, no. 3 (2012): 206-12. Abstract
"Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals." Drugs 72, no. 2 (2012): 217-28. Abstract
"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence." The New England journal of medicine 355, no. 4 (2006): 365-74. Abstract
"Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study." Journal of addiction medicine 6, no. 3 (2012): 205-11. Abstract
"The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S76-82. Abstract
"Cost and utilization outcomes of opioid-dependence treatments." The American journal of managed care 17 Suppl 8 (2011): S235-48. Abstract
"Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients." Drug and alcohol dependence 99, no. 1-3 (2009): 132-40. Abstract
"Coordination of medical care and opioid dependence treatment in primary care: a case report." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 24, no. 1 (2003): 43-6.
"Conventional and unconventional treatments for stress among methadone-maintained patients: treatment willingness and perceived efficacy." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 20, no. 2 (2011): 137-42. Abstract
"Consensus statement on office-based treatment of opioid dependence using buprenorphine." Journal of substance abuse treatment 27, no. 2 (2004): 153-9. Abstract
"Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening." The American journal of drug and alcohol abuse 35, no. 6 (2009): 439-44. Abstract
"Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners." Addiction (Abingdon, England) 105, no. 2 (2010): 224-5.
